Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CGP 25454A is a novel and selective antagonist of the presynaptic dopamine autoreceptor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 134.00 | |
5 mg | 5 days | $ 228.00 | |
25 mg | 6-8 weeks | $ 613.00 | |
50 mg | 6-8 weeks | $ 797.00 | |
100 mg | 6-8 weeks | $ 1,360.00 |
Description | CGP 25454A is a novel and selective antagonist of the presynaptic dopamine autoreceptor. |
In vitro | CGP 25454A increases the field-stimulated [3H]- and [14C]-overflow from rat striatal slices preloaded with [3H]dopamine and [14C]choline, indicating that CGP 25454A is able to enhance the release of both dopamine (DA) and acetylcholine (ACh). However, CGP 25454A is 12.9 times more potent in increasing, by 1/6 of the apparent maximal increase, the release of [3H]DA than that of [14C]ACh. |
In vivo | CGP 25454A increase [3H]spiperone binding to receptors of the D2 family in rat striatum by 90-110% (ED50: 13 mg/kg i.p.). At 30-100 mg/kg, CGP 25454A inhibits [3H]spiperone binding in the pituitary of the same animals as a result of a blockade of postsynaptic DA receptors. |
Molecular Weight | 346.25 |
Formula | C15H21Cl2N3O2 |
CAS No. | 104391-26-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.5 mg/mL (10.11 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CGP 25454A 104391-26-6 Others inhibitor inhibit